Predicting cytokine storms: It's about density

Blood

Volumn 118, Issue 26, 2011, Pages 6724-6726

  Frigault, Matthew J ^a   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOKINE; TGN 1412;

CD4+ T LYMPHOCYTE; CELL DENSITY; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DOSE RESPONSE; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; MACACA; MEMORY T LYMPHOCYTE; NONHUMAN; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84455172814     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-382598     Document Type: Note

References (11)

1. Römer P, Berr S, Avota E, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011;118(26):6772-6782.
2. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-1028. (Pubitemid 44343545)
3. Stebbings R, Findlay L, Edwards C, et al. "Cytokine storm" in the phase 1 trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol. 2007;179(5):3325-3331.
4. Findlay L, Eastwood D, Stebbings R, et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods. 2010;352(1-2):1-12.
5. Gogishvili T, Langenhorst D, Luhder F, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One. 2009;4(2):e4643.
6. Waibler Z, Sender L, Kamp C, et al. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J Allergy Clin Immunol. 2008;122(5):890-892.
7. Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161(3):512-526.
8. Paiardini M, Cervasi B, Reyes-Aviles E, et al. Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited CCR5 expression. Nat Med. 2011;17(7):830-836.
9. Fauci AS, Pratt KR. Polyclonal activation of bone-marrow-derived lymphocytes from human peripheral blood measured by a direct plaque-forming cell assay. Proc Natl Acad Sci U S A. 1976;73(1):3676-3679.
10. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex). J Immunother. 2010;33(3):305-315.
11. Saha B, Harlan DM, Lee KP, June CH, Abe R. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J Exp Med. 1996;183(6):2675-2680. (Pubitemid 26192377)